CAJ | 학술논문

目的：探讨血清脂蛋白（a）在血液恶性肿瘤中的变化及临床意义。方法回顾性分析我院诊治的130例血液恶性肿瘤患者血清脂蛋白（a）水平，并收集12例健康体检者作为正常对照，分析治疗前脂蛋白（a）水平、治疗前后脂蛋白（a）的变化及其对复发及生存时间的影响，并分析治疗前血清脂蛋白（a）水平与WBC、LDH水平的相关性。结果治疗前血液恶性肿瘤患者血清脂蛋白（a）水平明显升高（P＜0.05）；其中ANLL、ALL、淋巴瘤患者血清脂蛋白（a）水平明显升高（P＜0.05），而MM、MDS患者无统计学差异（P＞0.05）。治疗后血清脂蛋白（a）水平明显降低（P＜0.05），其中ANLL、ALL、MDS患者治疗后显著降低（P＜0.05），淋巴瘤、MM患者治疗后未显著降低（P＞0.05）。治疗前血清脂蛋白（a）水平升高组复发率为26.83%，中位生存期23个月；血清脂蛋白（a）水平正常组复发率为20.22%，中位生存期32个月，两组中位生存时间有统计学差异（P＜0.05）。治疗前血清脂蛋白（a）水平与WBC水平无显著相关性（r=0.021，P＞0.05），与LDH水平亦无显著相关性（r=0.035，P＞0.05）。结论血清脂蛋白（a）水平升高与血液恶性肿瘤密切相关，血清脂蛋白（a）可能是血液恶性肿瘤的不良预后因素。
목적：탐토혈청지단백（a）재혈액악성종류중적변화급림상의의。방법회고성분석아원진치적130례혈액악성종류환자혈청지단백（a）수평，병수집12례건강체검자작위정상대조，분석치료전지단백（a）수평、치료전후지단백（a）적변화급기대복발급생존시간적영향，병분석치료전혈청지단백（a）수평여WBC、LDH수평적상관성。결과치료전혈액악성종류환자혈청지단백（a）수평명현승고（P＜0.05）；기중ANLL、ALL、림파류환자혈청지단백（a）수평명현승고（P＜0.05），이MM、MDS환자무통계학차이（P＞0.05）。치료후혈청지단백（a）수평명현강저（P＜0.05），기중ANLL、ALL、MDS환자치료후현저강저（P＜0.05），림파류、MM환자치료후미현저강저（P＞0.05）。치료전혈청지단백（a）수평승고조복발솔위26.83%，중위생존기23개월；혈청지단백（a）수평정상조복발솔위20.22%，중위생존기32개월，량조중위생존시간유통계학차이（P＜0.05）。치료전혈청지단백（a）수평여WBC수평무현저상관성（r=0.021，P＞0.05），여LDH수평역무현저상관성（r=0.035，P＞0.05）。결론혈청지단백（a）수평승고여혈액악성종류밀절상관，혈청지단백（a）가능시혈액악성종류적불량예후인소。
Objective To explore the changes and clinical significance of serum lipoprotin (a) in hematological malignancy. Methods To analyze retrospectively the serum lipoprotin (a) levels of the one hundred and thirty patients with hematological malignancy who were treated in our hospital, and 12 cases of healthy persons were collected as normal control. To analyze the lipoprotein (a) levels before treatment, the changes of the lipoprotein (a) levels between prior treatment and posttreatment, its impact on recurrence and survival time, and the correlation of the lipoprotein (a) levels before treatment and the WBC, LDH levels. Results The serum lipoprotein (a) levels of the malignant patients with hematological malignancy increased significantly (P<0.05), compared with control group;The serum lipoprotein (a) levels of ANLL, ALL and lymphoma patients increased significantly (P<0.05), the serum lipoprotein (a) levels of MM and MDS patients had no changes with statistical difference (P>0.05), compared with control group. Serum lipoprotein (a) levels of posttreatment patients with hematological malignancy significantly decreased (P<0.05), compared with prior treatment; ANLL, ALL, and MDS patients’ serum lipoprotein (a) levels significantly decreased after treatment (P<0.05), Serum lipoprotein (a) levels of lymphoma and MM patients did not decrease after treatment (P>0.05). Before treatment the high serum lipoprotein (a) levels group's recurrence rate was 26.83%, with a median survival time of 23 months; the normal serum lipoprotein (a) levels group's recurrence rate was 20.22%, with a median survival time of 32 months, the median survival time of the two groups with statistical difference (P<0.05). The correlation of the lipoprotein (a) levels before treatment and the WBC levels had no statistical difference (r=0.021, P>0.05), the LDH levels had no statistical difference (r=0.035, P>0.05). Conclusion The high serum lipoprotein (a) levels are closely related to hematological malignancies. The serum lipoprotein (a) levels are likely to be a adverse prognostic factor for hematological malignancies.